AbbVie Inc.|4Feb 20, 6:35 PM ET

Crum Demetris D 4

4 · AbbVie Inc. · Filed Feb 20, 2026

AI-generated summary of this filing

Updated Feb 20, 2026

AbbVie (ABBV) EVP Demetris Crum Receives RSUs and Option Grant

What Happened

Demetris D. Crum, EVP and Chief HR Officer of AbbVie, reported awards on Feb 18, 2026: two performance-vesting restricted stock unit (RSU) releases totaling 2,460 shares (1,216 and 1,244) and a derivative award shown as 13,406 shares (an employee stock option). All items are reported with a $0 cash price because these are compensation awards/option grants, not open-market purchases or sales. The RSU releases were certified by the Compensation Committee and the shares are scheduled to be issued on Feb 28, 2026.

Key Details

Transaction date: 2026-02-18; reported/filed: 2026-02-20 (timely filing).
Reported prices/values: $0.00 for each award/derivative (compensation grants).
RSUs released: 1,216 and 1,244 shares (total 2,460) — awarded under performance-vesting RSU grants from Feb 15, 2024 and Feb 13, 2025; issuance set for Feb 28, 2026 (see F1, F2).
Option/derivative: 13,406-share employee stock option granted (see F3); becomes exercisable in annual increments of 4,469 on 2/18/2027, 4,469 on 2/18/2028 and 4,468 on 2/18/2029.
Shares owned after transaction: not specified in the excerpt provided.
Filing timeliness: filed Feb 20 for Feb 18 transactions — appears timely (not marked late).

Context

These entries are compensation-related awards/releases, not market purchases or sales; awards reported at $0 reflect grant/vesting, not a cash transaction. Performance RSUs were released after Certification of performance goals tied to a relative return-on-equity measure. The option is a standard employee grant with multi-year vesting; no indication in this filing that any shares were sold immediately.

Form 4

Period: 2026-02-18

EVP, CHIEF HR OFFICER

Transactions

Award
Common Stock, $0.01 par value
[F1]
2026-02-18+1,216→ 8,264 total
Award
Common Stock, $0.01 par value
[F2]
2026-02-18+1,244→ 9,508 total
Award
Option (Right to buy)
[F3]
2026-02-18+13,406→ 13,406 total
Exercise: $230.04Exp: 2036-02-17→ Common Stock (13,406 underlying)

Footnotes (3)

[F1]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
[F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
[F3]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,469 on February 18, 2027, 4,469 on February 18, 2028, and 4,468 on February 18, 2029.

Signature

/s/ T.O. Odutayo, Attorney-in-Fact for Demetris D. Crum|2026-02-20

1 file